


- 2 -



IA-IF

wherein: the carbon atom designated \* is in the R or S configuration;

$R^1$  is  $C_1$ - $C_6$  alkyl,  $C_2$ - $C_6$  alkenyl,  $C_2$ - $C_6$  alkynyl,  $C_3$ - $C_6$  cycloalkyl or  $C_4$ - $C_7$  cycloalkylalkyl, each of which is optionally substituted with 1 to 3 substituents independently selected at each occurrence thereof from  $C_1$ - $C_3$  alkyl, halogen, aryl, -CN,  $OR^9$  and  $-NR^9R^{10}$ ;

$R^2$  is H,  $C_1$ - $C_6$  alkyl,  $C_2$ - $C_6$  alkenyl,  $C_2$ - $C_6$  alkynyl,  $C_3$ - $C_6$  cycloalkyl,  $C_4$ - $C_7$  cycloalkylalkyl or  $C_1$ - $C_6$  haloalkyl;

$R^3$  is H, halogen,  $-S(O)_nR^{12}$ ,  $-S(O)_nNR^{11}R^{12}$ , -CN,  $-C(O)R^{12}$ ,  $-C(O)NR^{11}R^{12}$ ,  $C_1$ - $C_6$  alkyl,  $C_2$ - $C_6$  alkenyl,  $C_2$ - $C_6$  alkynyl,  $C_3$ - $C_6$  cycloalkyl,  $C_4$ - $C_7$  cycloalkylalkyl, -O(phenyl) or -O(benzyl), wherein each of -O(phenyl) and -O(benzyl) is optionally substituted from 1 to 3 times with a substituent selected independently at each occurrence thereof from halogen, cyano,  $C_1$ - $C_4$  alkyl,  $C_1$ - $C_4$  haloalkyl, or  $C_1$ - $C_4$  alkoxy, or wherein  $R^3$  is a  $C_1$ - $C_6$  alkyl,  $C_2$ - $C_6$  alkenyl,  $C_2$ - $C_6$  alkynyl,  $C_3$ - $C_6$  cycloalkyl or  $C_4$ - $C_7$  cycloalkylalkyl group, then said group is optionally substituted with from 1 to 3 substituents selected independently at each occurrence thereof from  $C_1$ - $C_3$  alkyl, halogen, aryl, -CN,  $-OR^9$  and  $-NR^9R^{10}$ ; provided that for compounds of formula IA,  $R^3$  is  $C_1$ - $C_6$  alkyl,  $C_2$ - $C_6$  alkenyl,  $C_2$ - $C_6$  alkynyl,  $C_3$ - $C_6$  cycloalkyl or  $C_4$ - $C_7$  cycloalkylalkyl, each of which is optionally substituted with from 1 to 3 substituents selected independently at each occurrence thereof from  $C_1$ - $C_3$  alkyl, halogen, aryl, -CN,  $-OR^9$  and  $-NR^9R^{10}$ ;

R691189.2

- 3 -

provided that for compounds of formula IB,  $R^3$  is  $-O(\text{phenyl})$ ,  $-O(\text{benzyl})$ ,  $-OC(O)R^{13}$  or  $S(O)_nR^{12}$ , each of  $-O(\text{phenyl})$  and  $-O(\text{benzyl})$  is optionally substituted from 1 to 3 times with a substituent selected independently at each occurrence thereof from halogen, cyano,  $C_1$ - $C_4$  alkyl,  $C_1$ - $C_4$  haloalkyl, or  $C_1$ - $C_4$  alkoxy;

$R^4$  is H, halogen,  $-S(O)_nR^{12}$ ,  $-S(O)NR^{11}R^{12}$ ,  $-CN$ ,  $-C(O)R^{12}$ ,  $-C(O)NR^{11}R^{12}$ ,  $-NR^{11}R^{12}$ ,  $C_1$ - $C_6$  alkyl,  $C_2$ - $C_6$  alkenyl,  $C_2$ - $C_6$  alkynyl,  $C_3$ - $C_6$  cycloalkyl,  $C_4$ - $C_7$  cycloalkylalkyl,  $-O(\text{phenyl})$  or  $-O(\text{benzyl})$ , wherein each of  $-O(\text{phenyl})$  and  $-O(\text{benzyl})$  is optionally substituted from 1 to 3 times with a substituent selected independently at each occurrence thereof from halogen, cyano,  $C_1$ - $C_4$  alkyl,  $C_1$ - $C_4$  haloalkyl, or  $C_1$ - $C_4$  alkoxy and wherein  $R^4$  is a  $C_1$ - $C_6$  alkyl,  $C_2$ - $C_6$  alkenyl,  $C_2$ - $C_6$  alkynyl,  $C_3$ - $C_6$  cycloalkyl or  $C_4$ - $C_7$  cycloalkylalkyl group, then said group is optionally substituted with from 1 to 3 substituents selected independently at each occurrence thereof from  $C_1$ - $C_3$  alkyl, halogen, aryl,  $-CN$ ,  $-OR^9$  and  $-NR^9R^{10}$ ; provided that for compounds of formula IC,  $R^4$  is  $C_1$ - $C_6$  alkyl,  $C_2$ - $C_6$  alkenyl,  $C_2$ - $C_6$  alkynyl,  $C_3$ - $C_6$  cycloalkyl or  $C_4$ - $C_7$  cycloalkylalkyl, each of which is optionally substituted; provided that for compounds of formula ID,  $R^4$  is  $-O(\text{phenyl})$ ,  $-O(\text{benzyl})$ ,  $-OC(O)R^{13}$ ,  $-NR^{11}R^{12}$  or  $-S(O)_nR^{12}$ , each of  $-O(\text{phenyl})$  and  $-O(\text{benzyl})$  being optionally substituted, wherein  $R^3$  and  $R^4$  are not both H;

$R^5$ ,  $R^6$  and  $R^7$  in compounds of each of the formulae IA, IB, IC, ID, IE and IF are each independently H, halogen,  $-OR^{11}$ ,  $-S(O)_nR^{12}$ ,  $-CN$ ,  $-C(O)R^{12}$ ,  $-NR^{11}R^{12}$ ,  $-C(O)NR^{11}R^{12}$ ,  $-NR^{11}C(O)R^{12}$ ,  $-NR^{11}C(O)_2R^{12}$ ,  $-NR^{11}C(O)NR^{12}R^{13}$ ,  $C_1$ - $C_6$  alkyl,  $C_2$ - $C_6$  alkenyl,  $C_2$ - $C_6$  alkynyl,  $C_3$ - $C_6$  cycloalkyl or  $C_4$ - $C_7$  cycloalkylalkyl, wherein each of  $R^5$ ,  $R^6$  and  $R^7$  is a  $C_1$ - $C_6$  alkyl,  $C_2$ - $C_6$  alkenyl,  $C_2$ - $C_6$  alkynyl,  $C_3$ - $C_6$  cycloalkyl or  $C_4$ - $C_7$  cycloalkylalkyl group, then said group is optionally substituted with from 1 to 3 substituents selected independently at each occurrence thereof from  $C_1$ - $C_3$  alkyl, halogen, aryl,  $-CN$ ,  $-OR^9$  and  $-NR^9R^{10}$ , or  $R^5$  and  $R^6$  or  $R^6$  and  $R^7$  may be  $-O-C(R^{12})_2-O-$ ; provided that for compounds of formula IE at least one of  $R^5$  or  $R^7$  is fluoro, chloro, or methyl; or  $R^5$  or  $R^6$  are each independently  $-O-C(R^{12})_2-O-$  in compounds of the formulae IE, but only where  $R^7$  is fluoro, chloro or methyl; or  $R^7$  and  $R^6$  can independently also be  $-O-C(R^{12})_2-O-$  in compounds of the formulae IE, but only where  $R^5$  is fluoro, chloro or methyl;

$R^8$  is H or halogen, provided that for compounds of formula IF,  $R^8$  is halogen;

$R^9$  and  $R^{10}$  are each independently H,  $C_1$ - $C_4$  alkyl,  $C_1$ - $C_4$  haloalkyl,  $C_1$ - $C_4$  alkoxyalkyl,  $C_3$ - $C_6$  cycloalkyl,  $C_4$ - $C_7$  cycloalkylalkyl,  $-C(O)R^{13}$ , phenyl or benzyl, where phenyl or benzyl is optionally substituted from 1 to 3 times with a substituent selected independently at each occurrence thereof from halogen, cyano,  $C_1$ - $C_4$  alkyl,  $C_1$ - $C_4$  haloalkyl,

or C<sub>1</sub>-C<sub>4</sub> alkoxy; or R<sup>9</sup> and R<sup>10</sup> are taken together with the nitrogen to which they are attached to form piperidine, pyrrolidine, piperazine, N-methylpiperazine, morpholine, or thiomorpholine;

R<sup>11</sup> is H, C<sub>1</sub>-C<sub>4</sub> alkyl, C<sub>1</sub>-C<sub>4</sub> haloalkyl, C<sub>1</sub>-C<sub>4</sub> alkoxyalkyl, C<sub>3</sub>-C<sub>6</sub> cycloalkyl, C<sub>4</sub>-C<sub>7</sub> cycloalkylalkyl, -C(O)R<sup>13</sup>, phenyl or benzyl, where R<sup>11</sup> is a C<sub>1</sub>-C<sub>4</sub> alkyl, phenyl or benzyl group, then said group is optionally substituted from 1 to 3 times with a substituent selected independently at each occurrence thereof from halogen, cyano, C<sub>1</sub>-C<sub>4</sub> alkyl, C<sub>1</sub>-C<sub>4</sub> haloalkyl, or C<sub>1</sub>-C<sub>4</sub> alkoxy;

R<sup>12</sup> is H, amino, C<sub>1</sub>-C<sub>4</sub> alkyl, (C<sub>1</sub>-C<sub>4</sub> alkyl)amino, C<sub>1</sub>-C<sub>4</sub> haloalkyl, C<sub>1</sub>-C<sub>4</sub> alkoxyalkyl, C<sub>3</sub>-C<sub>6</sub> cycloalkyl, C<sub>4</sub>-C<sub>7</sub> cycloalkylalkyl, phenyl or benzyl, where phenyl or benzyl is optionally substituted from 1 to 3 times with a substituent selected independently from halogen, cyano, C<sub>1</sub>-C<sub>4</sub> alkyl, C<sub>1</sub>-C<sub>4</sub> haloalkyl and C<sub>1</sub>-C<sub>4</sub> alkoxy; or R<sup>11</sup> and R<sup>12</sup> are taken together with the nitrogen to which they are attached to form piperidine, pyrrolidine, piperazine, N-methylpiperazine, morpholine, or thiomorpholine;

provided that only one of R<sup>9</sup> and R<sup>10</sup> or R<sup>9</sup> and R<sup>10</sup> are taken together with the nitrogen to which they are attached to form piperidine, pyrrolidine, piperazine, N-methylpiperazine, morpholine, or thiomorpholine;

R<sup>13</sup> is C<sub>1</sub>-C<sub>4</sub> alkyl, C<sub>1</sub>-C<sub>4</sub> haloalkyl or phenyl;

n is 0, 1, or 2, and;

aryl is phenyl which is optionally substituted 1-3 times with halogen, cyano, C<sub>1</sub>-C<sub>4</sub> alkyl, C<sub>1</sub>-C<sub>4</sub> haloalkyl and C<sub>1</sub>-C<sub>4</sub> alkoxy, or

an oxide thereof, or a pharmaceutically acceptable salt thereof, wherein the compound has a binding affinity for dopamine transporter protein to a binding affinity for norepinephrine transporter protein ratio of at least 2:1 and a binding affinity for serotonin transporter protein to a binding affinity for norepinephrine transporter protein ratio of at least 20:1.

52. The compound of claim 51, wherein R<sup>1</sup> is C<sub>1</sub>-C<sub>3</sub> alkyl.

53. The compound of claim 52, wherein R<sup>1</sup> is CH<sub>3</sub>.

54. The compound of claim 51, wherein R<sup>2</sup> is H, C<sub>1</sub>-C<sub>4</sub> alkyl or C<sub>1</sub>-C<sub>6</sub> haloalkyl.

55. The compound of claim 54, wherein R<sup>2</sup> is H or CH<sub>3</sub>.

56. The compound of claim 51, wherein  $R^3$  is H or  $R^3$  is  $C_1$ - $C_4$  alkyl,  $C_3$ - $C_6$  cycloalkyl or  $C_4$ - $C_7$  cycloalkylalkyl, each of which is optionally substituted with from 1 to 3 substituents selected independently at each occurrence thereof from  $C_1$ - $C_3$  alkyl, halogen, aryl, -CN, -OR<sup>9</sup> and -NR<sup>9</sup>R<sup>10</sup> or  $R^3$  is -O(phenyl) or -O(benzyl) optionally substituted from 1 to 3 times with a substituent selected independently at each occurrence thereof from halogen, cyano,  $C_1$ - $C_4$  alkyl,  $C_1$ - $C_4$  haloalkyl, or  $C_1$ - $C_4$  alkoxy.

57. The compound of claim 56, wherein  $R^3$  is methyl, ethyl, propyl, or isopropyl.

58. The compound of claim 56, wherein  $R^3$  is -O(phenyl) or -O-CH<sub>2</sub>-(phenyl), each of which is optionally substituted from 1 to 3 times with a substituent selected independently at each occurrence thereof from halogen, cyano,  $C_1$ - $C_4$  alkyl,  $C_1$ - $C_4$  haloalkyl, or  $C_1$ - $C_4$  alkoxy.

59. The compound of claim 56, wherein  $R^3$  is H.

60. The compound of claim 51, wherein  $R^4$  is H, or  $R^4$  is -NR<sup>11</sup>R<sup>12</sup> or  $R^4$  is  $C_1$ - $C_4$  alkyl,  $C_3$ - $C_6$  cycloalkyl or  $C_4$ - $C_7$  cycloalkylalkyl, each of which is optionally substituted, or wherein  $R^4$  is -O(phenyl) or -O(benzyl), each of which is optionally substituted from 1 to 3 times with a substituent selected independently at each occurrence thereof from halogen, cyano,  $C_1$ - $C_4$  alkyl,  $C_1$ - $C_4$  haloalkyl, or  $C_1$ - $C_4$  alkoxy.

61. The compound of claim 60, wherein  $R^4$  is methyl, ethyl, propyl, or isopropyl.

62. The compound of claim 60, wherein  $R^4$  is -O(phenyl) or -O(CH<sub>2</sub>)(phenyl), each of which is optionally substituted from 1 to 3 times with a substituent selected independently at each occurrence thereof from halogen, cyano,  $C_1$ - $C_4$  alkyl,  $C_1$ - $C_4$  haloalkyl, or  $C_1$ - $C_4$  alkoxy.

63. The compound of claim 60, wherein  $R^4$  is H.

64. The compound of claim 51, wherein  $R^3$  and  $R^4$  are each halogen.

- 6 -

65. The compound of claim 51, wherein one of  $R^3$  and  $R^4$  is H and the other is  $CH_3$ .

66. The compound of claim 51, wherein  $R^5$ ,  $R^6$  and  $R^7$  are each H, halogen,  $-OR^{11}$ ,  $-NR^{11}R^{12}$ ,  $C_1-C_6$  alkyl and substituted  $C_1-C_6$  alkyl.

67. The compound of claim 66, wherein  $R^5$ ,  $R^6$  and  $R^7$  are each H.

68. The compound of claim 66, wherein one of  $R^5$  or  $R^7$  is F, Cl, or Me and the other of  $R^5$  or  $R^7$  and  $R^6$  are H, halogen,  $-OR^{11}$ ,  $-NR^{11}R^{12}$ , or optionally substituted  $C_1-C_6$  alkyl.

69. The compound of claim 68, wherein  $R^5$  is F, Cl or Me; and  $R^7$  is H.

70. The compound of claim 68, wherein  $R^5$  is F, Cl or Me; and  $R^6$  is H.

71. The compound of claim 51, wherein  $R^8$  is halogen.

72. The compound of claim 71, wherein  $R^8$  is fluoro.

73. The compound of claim 51, wherein:

$R^1$  is  $C_1-C_3$  alkyl;

$R^2$  is H,  $C_1-C_4$  alkyl or  $C_1-C_6$  haloalkyl;

$R^3$  is  $C_1-C_4$  alkyl,  $C_3-C_6$  cycloalkyl or  $C_4-C_7$  cycloalkylalkyl, each of which is optionally substituted, or  $R^3$  is  $-O(\text{phenyl})$  or  $-O(\text{benzyl})$ , each of which is optionally substituted, or  $R^3$  is H;

$R^4$  is H,  $C_1-C_4$  alkyl,  $C_3-C_6$  cycloalkyl or  $C_4-C_7$  cycloalkylalkyl, each of which is optionally substituted with from 1 to 3 substituents selected independently at each occurrence thereof from  $C_1-C_3$  alkyl, halogen, aryl,  $-CN$ ,  $-OR^9$  and  $-NR^9R^{10}$ , or  $R^4$  is  $-NR^{11}R^{12}$ ,  $-O(\text{phenyl})$  or  $-O(\text{benzyl})$ , wherein said  $-O(\text{phenyl})$  or  $-O(\text{benzyl})$ , is optionally substituted from 1 to 3 times with a substituent selected independently at each occurrence thereof from halogen, cyano,  $C_1-C_4$  alkyl,  $C_1-C_4$  haloalkyl, or  $C_1-C_4$  alkoxy.

or  $R^3$  and  $R^4$  are each halogen;

R.691189.2

- 7 -

$R^5$ ,  $R^6$  and  $R^7$  are each halogen,  $-OR^{11}$ ,  $-NR^{11}R^{12}$ , optionally  $C_1-C_6$  alkyl, or one of  $R^5$  and  $R^7$  is Cl, F or Me and the other of  $R^5$  and  $R^7$  and  $R^6$  is H, halogen,  $-NR^{11}R^{12}$ ,  $C_1-C_6$  alkyl or substituted  $C_1-C_6$  alkyl.

74. The compound of claim 51, wherein:

$R^1$  is  $CH_3$ ;

$R^2$  is H or  $CH_3$ ;

$R^3$  is H, F, methyl, ethyl, propyl, isopropyl,  $-O(\text{phenyl})$  or  $-O-CH_2-(\text{phenyl})$ , wherein said  $-O(\text{phenyl})$  or  $-O-CH_2-(\text{phenyl})$  is optionally substituted from 1 to 3 times with a substituent selected independently at each occurrence thereof from halogen, cyano,  $C_1-C_4$  alkyl,  $C_1-C_4$  haloalkyl, or  $C_1-C_4$  alkoxy;

$R^4$  is H, F methyl, ethyl, propyl, isopropyl,  $-O(\text{phenyl})$  or  $-O-CH_2-(\text{phenyl})$ , wherein said  $-O(\text{phenyl})$  or  $-O-CH_2-(\text{phenyl})$  is optionally substituted from 1 to 3 times with a substituent selected independently at each occurrence thereof from halogen, cyano,  $C_1-C_4$  alkyl,  $C_1-C_4$  haloalkyl, or  $C_1-C_4$  alkoxy;

$R^5$ ,  $R^6$  and  $R^7$  are each H or  $R^5$  is F, Cl or Me, or one of  $R^6$  or  $R^7$  is H and the other of  $R^6$  and  $R^7$  is halogen,  $-OR^{11}$ ,  $-NR^{11}R^{12}$ , or optionally substituted  $C_1-C_6$  alkyl.

75. The compound of claim 73, wherein  $R^8$  is halogen.

76. The compound according to claim 51, wherein the carbon atom designated \* is in the R configuration.

77. The compound according to claim 51, wherein the carbon atom designated \* is in the S configuration.

78. A composition comprising a mixture of stereoisomeric compounds of claim 51 wherein the carbon atom designated \* is in the S or R configuration.

79. The compound according to claim 51, selected from the group consisting of the following compounds:

4-(4-methoxy)phenyl-2,7-dimethyl-1,2,3,4-tetrahydroisoquinoline;

2,7-dimethyl-4-(4-fluoro)phenyl-1,2,3,4-tetrahydroisoquinoline;

2,7-dimethyl-4-(3-fluoro)phenyl-1,2,3,4-tetrahydroisoquinoline;

4-(3,4-difluoro)phenyl-2,7-dimethyl-1,2,3,4-tetrahydroisoquinoline;  
2,7-dimethyl-4-(4-fluoro-3-methyl)phenyl-1,2,3,4-tetrahydroisoquinoline;  
4-(3-chloro-4-fluoro)phenyl-2,7-dimethyl-1,2,3,4-tetrahydroisoquinoline;  
4-(3-chloro)phenyl-2,7-dimethyl-1,2,3,4-tetrahydroisoquinoline;  
2,7-dimethyl-4-(4-methyl)phenyl-1,2,3,4-tetrahydroisoquinoline;  
2,7-dimethyl-4-(3-fluoro-4-methyl)phenyl-1,2,3,4-tetrahydroisoquinoline;  
4-(4-chloro)phenyl-2,7-dimethyl-1,2,3,4-tetrahydroisoquinoline;  
4-(4-chloro-3-fluoro)phenyl-2,7-dimethyl-1,2,3,4-tetrahydroisoquinoline;  
4-(3,4-dichloro)phenyl-2,7-dimethyl-1,2,3,4-tetrahydroisoquinoline;  
7-ethyl-2-methyl-4-phenyl-1,2,3,4-tetrahydroisoquinoline;  
4-(3,4-difluoro)phenyl-7-ethyl-2-methyl-1,2,3,4-tetrahydroisoquinoline;  
7-fluoro-4-(4-methoxy)phenyl-2-methyl-1,2,3,4-tetrahydroisoquinoline;  
7-fluoro-4-(3-fluoro-4-methoxy)phenyl-2-methyl-1,2,3,4-tetrahydroisoquinoline;  
7-fluoro-4-(3-fluoro-4-methyl)phenyl-2-methyl-1,2,3,4-tetrahydroisoquinoline;  
7-fluoro-4-(4-chloro-3-fluoro)phenyl-2-methyl-1,2,3,4-tetrahydroisoquinoline;  
4-(3,4-difluoro)phenyl-7-fluoro-2-methyl-1,2,3,4-tetrahydroisoquinoline;  
4-(3-chloro)phenyl-7-fluoro-2-methyl-1,2,3,4-tetrahydroisoquinoline;  
7-cyano-2-methyl-4-phenyl-1,2,3,4-tetrahydroisoquinoline;  
2-methyl-4-phenyl-7-trifluoromethyl-1,2,3,4-tetrahydroisoquinoline;  
4-phenyl-1,2,7-trimethyl-1,2,3,4-tetrahydroisoquinoline;  
4-phenyl-2,7,8-trifluoromethyl-1,2,3,4-tetrahydroisoquinoline;  
2,7-dimethyl-8-fluoro-4-phenyl-1,2,3,4-tetrahydroisoquinoline;  
2,8-dimethyl-7-fluoro-4-phenyl-1,2,3,4-tetrahydroisoquinoline;  
2-methyl-7-phenoxy-4-phenyl-1,2,3,4-tetrahydroisoquinoline;  
7-(4-methoxy)phenoxy-2-methyl-4-phenyl-1,2,3,4-tetrahydroisoquinoline;  
7-benzyloxy-2-methyl-4-phenyl-1,2,3,4-tetrahydroisoquinoline;  
2,8-dimethyl-4-(4-fluoro)phenyl-1,2,3,4-tetrahydroisoquinoline;  
4-(3,4-difluoro)phenyl-2,8-dimethyl-1,2,3,4-tetrahydroisoquinoline;  
4-(3,5-difluoro)phenyl-2,8-dimethyl-1,2,3,4-tetrahydroisoquinoline;  
2,8-dimethyl-4-(3-fluoro)phenyl-1,2,3,4-tetrahydroisoquinoline;  
2,8-dimethyl-4-(4-fluoro-3-methyl)phenyl-1,2,3,4-tetrahydroisoquinoline;  
4-(3-chloro-4-fluoro)phenyl-2,8-dimethyl-1,2,3,4-tetrahydroisoquinoline;  
4-(3,4-dichloro)phenyl-2,8-dimethyl-1,2,3,4-tetrahydroisoquinoline;  
4-(3-chloro)phenyl-2,8-dimethyl-1,2,3,4-tetrahydroisoquinoline;

4-(4-chloro)phenyl-2,8-dimethyl-1,2,3,4-tetrahydroisoquinoline;  
 4-(4-chloro-3-fluoro)phenyl-2,8-dimethyl-1,2,3,4-tetrahydroisoquinoline;  
 2,8-dimethyl-4-(4-methoxy)phenyl-1,2,3,4-tetrahydroisoquinoline;  
 4-(4-cyano)phenyl-2,8-dimethyl-1,2,3,4-tetrahydroisoquinoline;  
 2,8-dimethyl-4-(4-trifluoromethyl)phenyl-1,2,3,4-tetrahydroisoquinoline;  
 2,8-dimethyl-4-(4-methyl)phenyl-1,2,3,4-tetrahydroisoquinoline;  
 2-methyl-8-(N-methylamino)methyl-4-phenyl-1,2,3,4-tetrahydroisoquinoline;  
 8-(hydroxy)methyl-2-methyl-4-phenyl-1,2,3,4-tetrahydroisoquinoline;  
 2-methyl-4-phenyl-8-sulfonamide-1,2,3,4-tetrahydroisoquinoline;  
 2-methyl-8-(N-methyl)sulfonamide-4-phenyl-1,2,3,4-tetrahydroisoquinoline;  
 4-(3,5-difluoro)phenyl-2,7-dimethyl-1,2,3,4-tetrahydroisoquinoline;  
 4-(3-chloro-5-fluoro)phenyl-2,7-dimethyl-1,2,3,4-tetrahydroisoquinoline;  
 4-(3,5-difluorophenyl-1,2,7-trimethyl-1,2,3,4-tetrahydroisoquinoline;  
 (8-fluoro-2-methyl-4-phenyl-1,2,3,4-tetrahydro-7-isoquinoliny)-N-methylmethanami

ne;

2-methyl-4-phenyl-1,2,3,4-tetrahydro-7-isoquinoliny)-N-methylmethanamine;

N-methyl(2-methyl-4-phenyl-1,2,3,4-tetrahydro-

7-isoquinoliny)-N-methylmethanamine;

(2-methyl-4-phenyl-1,2,3,4-tetrahydro-7-isoquinoliny)methanol; and

an oxide thereof, or a pharmaceutically acceptable salt thereof.

80. The compound according to claim 51, selected from the group consisting of the following compounds:

Sub  
C2

	R <sup>1</sup>	R <sup>2</sup>	R <sup>3</sup>	R <sup>4</sup>	R <sup>5</sup>	R <sup>6</sup>	R <sup>7</sup>	R <sup>8</sup>
1.	Me	H	H	Me	H	OMe	H	H
2.	Me	H	H	Me	H	F	H	H
3.	Me	H	H	Me	F	H	H	H
4.	Me	H	H	Me	F	F	H	H
5.	Me	H	H	Me	Me	F	H	H
6.	Me	H	H	Me	Cl	F	H	H
7.	Me	H	H	Me	Cl	H	H	H
8.	Me	H	H	Me	H	Me	H	H



- 10 -

Sub  
C2

B1

	R <sup>1</sup>	R <sup>2</sup>	R <sup>3</sup>	R <sup>4</sup>	R <sup>5</sup>	R <sup>6</sup>	R <sup>7</sup>	R <sup>8</sup>
9.	Me	H	H	Me	F	Me	H	H
10.	Me	H	H	Me	H	Cl	H	H
11.	Me	H	H	Me	F	Cl	H	H
12.	Me	H	H	Me	Cl	Cl	H	H
13.	Me	H	H	Et	H	H	H	H
14.	Me	H	H	Et	F	F	H	H
15.	Me	H	H	F	H	OMe	H	H
16.	Me	H	H	F	F	OMe	H	H
17.	Me	H	H	F	F	Me	H	H
18.	Me	H	H	F	F	Cl	H	H
19.	Me	H	H	F	F	F	H	H
20.	Me	H	H	F	Cl	H	H	H
21.	Me	H	H	CN	H	H	H	H
22.	Me	H	H	CF <sub>3</sub>	H	H	H	H
23.	Me	Me	H	Me	H	H	H	H
24.	Me	H	Me	Me	H	H	H	H
25.	Me	H	F	Me	H	H	H	H
26.	Me	H	Me	F	H	H	H	H
27.	Me	H	H	O(Ph)	H	H	H	H
28.	Me	H	H	O(4-OmePh)	H	H	H	H
29.	Me	H	H	O(CH <sub>2</sub> Ph)	H	H	H	H
30.	Me	H	Me	H	H	F	H	H
31.	Me	H	Me	H	F	F	H	H
32.	Me	H	Me	H	F	H	F	H
33.	Me	H	Me	H	F	H	H	H
34.	Me	H	Me	H	Me	F	H	H
35.	Me	H	Me	H	Cl	F	H	H
36.	Me	H	Me	H	Cl	Cl	H	H
37.	Me	H	Me	H	Cl	H	H	H
38.	Me	H	Me	H	H	Cl	H	H
39.	Me	H	Me	H	F	Cl	H	H
40.	Me	H	Me	H	H	OMe	H	H

R691189.2

Sub  
C2

B1

	R <sup>1</sup>	R <sup>2</sup>	R <sup>3</sup>	R <sup>4</sup>	R <sup>5</sup>	R <sup>6</sup>	R <sup>7</sup>	R <sup>8</sup>
41.	Me	H	Me	H	H	CN	H	H
42.	Me	H	Me	H	H	CF <sub>3</sub>	H	H
43.	Me	H	Me	H	H	Me	H	H
44.	Me	H	CH <sub>2</sub> NHMe	H	H	H	H	H
45.	Me	H	CH <sub>2</sub> OH	H	H	H	H	H
46.	Me	H	SO <sub>2</sub> NH <sub>2</sub>	H	H	H	H	H
47.	Me	H	SO <sub>2</sub> NHMe	H	H	H	H	H
48.	Me	H	H	Me	F	H	F	H
49.	Me	H	H	Me	F	H	Cl	H
50.	Me	Me	H	Me	F	H	F	H
51.	Me	H	H	Me	F	F	F	H
52.	Et	H	H	Me	H	F	H	H
53.	Me	H	F	CH <sub>2</sub> Me	H	H	H	H
54.	Me	H	H	CH <sub>2</sub> NH <sub>2</sub>	H	H	H	H
55.	Me	H	H	CH <sub>2</sub> NHMe	H	H	H	H
56.	Me	H	H	CH <sub>2</sub> OH	H	H	H	H

81. The compound according to claim 51, wherein the enantiomer is selected from the group consisting of the following compounds:

	<u>R<sup>1</sup></u>	<u>R<sup>2</sup></u>	<u>R<sup>3</sup></u>	<u>R<sup>4</sup></u>
1.	Me	H	F	F
2.	Me	F	H	F
3.	Me	H	F	H
4.	Me	H	H	F

82. The compound according to claim 79, which is the (+) stereoisomer.

83. The compound according to claim 79, which is the (-) stereoisomer.

84. A pharmaceutical composition comprising a pharmaceutically acceptable carrier and a therapeutically effective amount of the compound of claim 51.

85. A method of treating a disorder which is created by or is dependent upon decreased availability of serotonin, norepinephrine or dopamine, which comprises administering to a patient in need of such treatment a therapeutically effective amount of a compound according to claim 51, or a pharmaceutically acceptable salt thereof.

86. The method according to claim 85, wherein the disorder is selected from the group: attention deficit disorder, hyperactivity disorder, anxiety, depression, post-traumatic stress disorder, supranuclear palsy, eating disorders, obsessive compulsive disorder, analgesia, nicotine addiction, panic attacks, Parkinsonism and phobia, obesity, late luteal phase syndrome or narcolepsy, cocaine addiction, amphetamine addiction, and psychiatric symptoms anger such as, rejection sensitivity, and lack of mental or physical energy.

87. A method of inhibiting synaptic norepinephrine uptake in a patient in need thereof comprising administering a therapeutically effective inhibitory amount of a compound according to claim 51.

88. A method of inhibiting synaptic serotonin uptake in a patient in need thereof comprising administering a therapeutically effective inhibitory amount of a compound according to claim 51.

89. A method of inhibiting synaptic dopamine uptake in a patient in need thereof comprising administering a therapeutically effective inhibitory amount of a compound according to claim 51.

90. The method of claim 85 wherein the (+)-stereoisomer of the compound is employed.

91. The method of claim 85, wherein the (-)-stereoisomer of the compound is employed.

92. The method of claim 85 for treating attention deficit/hyperactivity disorder.